RU2016146119A - Новый кристалл тетрациклического соединения - Google Patents
Новый кристалл тетрациклического соединения Download PDFInfo
- Publication number
- RU2016146119A RU2016146119A RU2016146119A RU2016146119A RU2016146119A RU 2016146119 A RU2016146119 A RU 2016146119A RU 2016146119 A RU2016146119 A RU 2016146119A RU 2016146119 A RU2016146119 A RU 2016146119A RU 2016146119 A RU2016146119 A RU 2016146119A
- Authority
- RU
- Russia
- Prior art keywords
- new crystal
- crystal
- tetracyclic compound
- ray powder
- contains peaks
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Claims (5)
1. Кристалл моногидрохлорида соединения, представленного формулой (I), порошковая рентгеновская дифрактограмма которого содержит пики при дифракционных углах (2θ) 9,2°±0,2°, 10,2°±0,2°, 16,2°±0,2°, 20,5°±0,2° и 21,6°±0,2°.
2. Кристалл по п. 1, порошковая рентгеновская дифрактограмма которого содержит пики при дифракционных углах (2θ) 9,2°±0,2°, 10,2°±0,2°, 16,2°±0,2°, 17,5°±0,2°, 19,5°±0,2°, 20,5°±0,2°, 21,6°±0,2° и 22,8°±0,2°.
3. Кристалл по п. 1 или 2, который представляет собой кристалл моногидрата.
4. Кристалл моногидрохлорида соединения, представленного формулой (I), порошковая рентгеновская дифрактограмма которого содержит пики при дифракционных углах (2θ) 12,7°±0,2°, 14,3°±0,2°, 15,0°±0,2°, 18,5°±0,2 и 25,7°±0,2°.
5. Кристалл по п. 4, порошковая рентгеновская дифрактограмма которого содержит пики при дифракционных углах (2θ) 7,5°±0,2°, 12,7°±0,2°, 14,3°±0,2°, 15,0°±0,2°, 18,5°±0,2°, 20,3°±0,2°, 21,0°±0,2° и 25,7°±0,2°.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014092102 | 2014-04-25 | ||
| JP2014-092102 | 2014-04-25 | ||
| PCT/JP2015/062516 WO2015163447A1 (ja) | 2014-04-25 | 2015-04-24 | ４環性化合物の新規結晶 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016146119A true RU2016146119A (ru) | 2018-05-29 |
| RU2016146119A3 RU2016146119A3 (ru) | 2018-07-04 |
Family
ID=54332607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016146119A RU2016146119A (ru) | 2014-04-25 | 2015-04-24 | Новый кристалл тетрациклического соединения |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9714229B2 (ru) |
| EP (1) | EP3135671B1 (ru) |
| JP (1) | JP6873698B2 (ru) |
| KR (2) | KR20160142383A (ru) |
| CN (2) | CN106458967A (ru) |
| CA (1) | CA2946268A1 (ru) |
| MX (1) | MX2016013735A (ru) |
| RU (1) | RU2016146119A (ru) |
| WO (1) | WO2015163447A1 (ru) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2975024T3 (en) * | 2009-06-10 | 2018-04-23 | Chugai Pharmaceutical Co Ltd | Tetracyclic compounds |
| EP2606886B1 (en) | 2010-08-20 | 2020-01-08 | Chugai Seiyaku Kabushiki Kaisha | Composition comprising tetracyclic compound |
| CN111388478A (zh) | 2012-09-25 | 2020-07-10 | 中外制药株式会社 | Ret抑制剂 |
| AR100187A1 (es) | 2014-04-25 | 2016-09-14 | Chugai Pharmaceutical Co Ltd | Composición farmacéutica que contiene un inhibidor de alk (quinasa de linfoma anaplásico) |
| TWI765410B (zh) | 2014-08-08 | 2022-05-21 | 日商中外製藥股份有限公司 | ４環性化合物的非晶質體的用途 |
| WO2016114375A1 (ja) | 2015-01-16 | 2016-07-21 | 中外製薬株式会社 | 併用医薬 |
| US11098037B2 (en) | 2017-07-05 | 2021-08-24 | Fresenius Kabi Oncology Ltd. | Process for preparing alectinib or a pharmaceutically acceptable salt thereof |
| TW202019430A (zh) | 2018-06-29 | 2020-06-01 | 日商中外製藥股份有限公司 | 含有難溶性鹼性藥劑的醫藥組成物 |
| CN112585126B (zh) | 2018-09-04 | 2024-05-07 | 中外制药株式会社 | 四环化合物的制备方法 |
| EP3556754A1 (en) | 2018-12-07 | 2019-10-23 | Fresenius Kabi iPSUM S.r.l. | Process for the preparation of alectinib |
| AR121187A1 (es) | 2019-12-27 | 2022-04-27 | Chugai Pharmaceutical Co Ltd | Método para clasificar, evaluar o fabricar lauril sulfato de sodio de materia prima o formulación farmacéutica que lo contiene |
| JP7419572B2 (ja) | 2021-01-29 | 2024-01-22 | 中外製薬株式会社 | 小児がん治療用医薬組成物 |
| WO2023074785A1 (ja) | 2021-10-28 | 2023-05-04 | 中外製薬株式会社 | シロップ剤 |
| WO2023161233A1 (en) | 2022-02-22 | 2023-08-31 | Synthon B.V. | Solid forms of alectinib and alectinib salts |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0892090A (ja) | 1994-07-26 | 1996-04-09 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| EP0695755B1 (en) | 1994-08-04 | 1998-10-21 | F. Hoffmann-La Roche AG | Pyrrolocarbazole |
| IL126762A0 (en) | 1996-05-01 | 1999-08-17 | Lilly Co Eli | Halo-substituted protein kinase c inhibitors |
| WO2000069856A1 (en) | 1999-05-14 | 2000-11-23 | The Australian National University | Compounds and therapeutic methods |
| AU2256702A (en) | 2000-12-01 | 2002-06-11 | Kyowa Hakko Kogyo Kk | Composition improved in solubility or oral absorbability |
| US7217709B2 (en) | 2003-02-28 | 2007-05-15 | Inotek Pharmaceuticals Corporation | Tetracyclic benzamide derivatives and methods of use thereof |
| DE60305634T2 (de) | 2003-03-07 | 2006-09-21 | Istituto Nazionale Per Lo Studio E La Cura Dei Tumori | Anaplastisches Lymphoma Kinase Testverfahren, Reagenzien und Kompositionen davon |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| AU2004259012C1 (en) | 2003-07-23 | 2012-08-02 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| US7378414B2 (en) | 2003-08-25 | 2008-05-27 | Abbott Laboratories | Anti-infective agents |
| CA2546117A1 (en) | 2003-11-21 | 2005-06-16 | Novartis Ag | 1h-imidazoquinoline derivatives as protein kinase inhibitors |
| AU2004296905A1 (en) | 2003-12-12 | 2005-06-23 | Merck Frosst Canada Ltd | Cathepsin cysteine protease inhibitors |
| EP1725530A1 (en) | 2004-03-19 | 2006-11-29 | Speedel Experimenta AG | Organic compounds |
| EP1730128A1 (en) | 2004-03-31 | 2006-12-13 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| RS51362B (en) | 2004-08-26 | 2011-02-28 | Pfizer Inc. | ENANTIOMERALLY PURE AMINOHETEROARYL UNITS AS PROTEIN KINASE INHIBITORS |
| GB0517329D0 (en) | 2005-08-25 | 2005-10-05 | Merck Sharp & Dohme | Stimulation of neurogenesis |
| RU2008122547A (ru) | 2005-11-07 | 2009-12-20 | Айрм Ллк (Bm) | Соединения и композиции как модуляторы арпп (активированных рецепторов пролифератора пероксисом) |
| US7601716B2 (en) | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
| US8063225B2 (en) | 2006-08-14 | 2011-11-22 | Chembridge Corporation | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
| CA2598893C (en) | 2006-10-11 | 2012-04-10 | Astellas Pharma Inc. | Eml4-alk fusion gene |
| EP1914240B1 (en) | 2006-10-11 | 2009-12-02 | Astellas Pharma Inc. | EML4-ALK fusion gene |
| EP2684874B1 (en) | 2006-10-23 | 2017-05-17 | Cephalon, Inc. | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors |
| JP2010524953A (ja) | 2007-04-17 | 2010-07-22 | ブリストル−マイヤーズ スクイブ カンパニー | 縮合ヘテロ環１１−β−ヒドロキシステロイドデヒドロゲナーゼＩ型阻害剤 |
| TWI389893B (zh) | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | 二（芳胺基）芳基化合物 |
| EP2176231B1 (en) | 2007-07-20 | 2016-10-19 | Nerviano Medical Sciences S.r.l. | Substituted indazole derivatives active as kinase inhibitors |
| JP5583592B2 (ja) | 2007-11-30 | 2014-09-03 | ニューリンク ジェネティクス コーポレイション | Ｉｄｏ阻害剤 |
| CN102574830A (zh) | 2009-05-07 | 2012-07-11 | 阿斯利康(瑞典)有限公司 | 取代的1-氰基乙基杂环基甲酰胺化合物750 |
| GB0910046D0 (en) | 2009-06-10 | 2009-07-22 | Glaxosmithkline Biolog Sa | Novel compositions |
| DK2975024T3 (en) | 2009-06-10 | 2018-04-23 | Chugai Pharmaceutical Co Ltd | Tetracyclic compounds |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| EP2606886B1 (en) | 2010-08-20 | 2020-01-08 | Chugai Seiyaku Kabushiki Kaisha | Composition comprising tetracyclic compound |
| JP5006987B2 (ja) * | 2010-11-22 | 2012-08-22 | 中外製薬株式会社 | ４環性化合物を含む医薬 |
| CN111388478A (zh) | 2012-09-25 | 2020-07-10 | 中外制药株式会社 | Ret抑制剂 |
| JP2015185406A (ja) | 2014-03-25 | 2015-10-22 | トヨタ自動車株式会社 | 燃料電池システム及び燃料電池の水分量制御方法 |
-
2015
- 2015-04-24 US US15/126,045 patent/US9714229B2/en active Active
- 2015-04-24 KR KR1020167031032A patent/KR20160142383A/ko not_active Application Discontinuation
- 2015-04-24 MX MX2016013735A patent/MX2016013735A/es unknown
- 2015-04-24 JP JP2016515222A patent/JP6873698B2/ja active Active
- 2015-04-24 CN CN201580020748.0A patent/CN106458967A/zh active Pending
- 2015-04-24 RU RU2016146119A patent/RU2016146119A/ru unknown
- 2015-04-24 CA CA2946268A patent/CA2946268A1/en active Pending
- 2015-04-24 WO PCT/JP2015/062516 patent/WO2015163447A1/ja active Application Filing
- 2015-04-24 EP EP15782464.0A patent/EP3135671B1/en active Active
- 2015-04-24 KR KR1020227009664A patent/KR20220042486A/ko not_active Application Discontinuation
- 2015-04-24 CN CN202110843684.1A patent/CN113416179A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP6873698B2 (ja) | 2021-05-19 |
| KR20160142383A (ko) | 2016-12-12 |
| EP3135671B1 (en) | 2019-09-18 |
| CN113416179A (zh) | 2021-09-21 |
| EP3135671A1 (en) | 2017-03-01 |
| JPWO2015163447A1 (ja) | 2017-04-20 |
| CA2946268A1 (en) | 2015-10-29 |
| EP3135671A4 (en) | 2017-11-22 |
| MX2016013735A (es) | 2017-03-09 |
| US9714229B2 (en) | 2017-07-25 |
| WO2015163447A1 (ja) | 2015-10-29 |
| KR20220042486A (ko) | 2022-04-05 |
| US20170081306A1 (en) | 2017-03-23 |
| RU2016146119A3 (ru) | 2018-07-04 |
| CN106458967A (zh) | 2017-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016146119A (ru) | Новый кристалл тетрациклического соединения | |
| PH12015502031A1 (en) | Tetrahydropyrrolothiazine compounds | |
| MX2017006266A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos. | |
| TN2015000175A1 (en) | Heteroaryl substituted pyridyl compounds useful as kinase modulators | |
| PH12016501614A1 (en) | Heterocyclic compound | |
| NZ714283A (en) | Novel histone deacetylase inhibitors | |
| JO3472B1 (ar) | مركبات ديهايدروبنزوفوران مفيدة في علاج السكري والسمنة | |
| WO2016071435A3 (en) | Synthesis of copanlisib and its dihydrochloride salt | |
| WO2015008218A3 (en) | Process for the preparation of suvorexant and intermediates useful in the synthesis of suvorexant | |
| MX2015017156A (es) | Inhibidores de bace. | |
| MA39866A (fr) | Amides 2-amino-6-méthyl-4,4a,5,6-tétrahydropyrano[3,4-d][1,3]thiazin-8a(8h)-yl-1,3-thiazol-4-yle | |
| EA201591915A1 (ru) | Соединения феноксиэтил дигидро-1h-изохинолина | |
| AR095097A1 (es) | Compuestos de fenoxietoxi | |
| MX2017005422A (es) | Inhibidores de histona desacetilasa y sus usos en terapia. | |
| PH12017501404A1 (en) | Diaza-benzofluoranthrene compounds | |
| EA201892449A1 (ru) | Конденсированные гетероциклические соединения | |
| JP2015506941A5 (ru) | ||
| WO2016088081A8 (en) | Processes for the preparation of ertugliflozin | |
| WO2017098533A3 (en) | Process for preparation of lisdexamphetamine | |
| EA201690593A1 (ru) | Новые соединения мочевины | |
| EA201690908A1 (ru) | Пиразолопиримидиновые соединения | |
| WO2015102017A8 (en) | Processes for the preparation of lorcaserin | |
| BR112015030589A2 (pt) | formas polimórficas de fosfato de icotinibe e seus usos | |
| RU2016145264A (ru) | Соли и полиморфы замещенного имидазопиридинил-аминопиридина | |
| EA201400269A1 (ru) | Способ синтеза соединений 7,8-диметокси -1,3-дигидро-2h-3-бензазепин-2-она и применение в синтезе ивабрадина |